


## Agilis GTRI Japan Inc. (USA)

- ◆ Its parent company is a biotech company that conducts clinical development of gene therapy. It has world-class technology and knowhow regarding gene therapy for rare diseases such as AADC deficiency, using AAV vectors (a virus that is used for transfection of therapeutic genes into cells). This technology is drawing attention from all over the world.
- ◆ It has established a subsidiary (a joint venture with a Japanese company) and a new R&D center in the Life Science Innovation Center of Kawasaki City in order to conduct R&D for efficient and safe production of AAV vectors for gene therapy targeting AADC deficiency and Parkinson's disease, in collaboration with a Japanese company (Gene Therapy Research Institution).
- ◆ If development of mass-produced and low-cost therapeutic drugs for AADC deficiency and Parkinson's disease (for which radical therapies do not yet exist) are realized, the burden on patients will drop, and the effectiveness of treatment is expected to be long-lasting. The company is also eyeing exportation to overseas.

### Regenerative medicine



<http://www.agilisbio.com/>